Reference:	FOI.12779.23
Subject:	Coagulation factors
Date of Request:	1 October 2023

Requested:

1. In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:

    a. Hemlibra (non-inhibitor patients)
    b. Hemlibra (inhibitor patients)
    c. Advate
    d. Adynovi
    e. Elocta
    f. Esperoct
    g. NovoEight
    h. ReFacto AF
    i. Nuwiq
    j. Idelvion
    k. Refixia
    l. Alprolix
    m. BeneFIX
    n. Replenine
    o. Rixubis
    p. Voncento
    q. Veyvondi
    r. Wilate
    s. Willfact
    t. Alphanate
    u. Octanate
    v. Optivate
    w. Fahndi
    x. Haemate

2. In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:

    a. Hemlibra (non-inhibitor patients)
    b. Hemlibra (inhibitor patients)
    c. Advate
    d. Adynovi
    e. Elocta
    f. Esperoct
    g. NovoEight
    h. ReFacto AF
    i. Nuwiq
    j. Idelvion
    k. Refixia
    l. Alprolix
    m. BeneFIX

n. Replenine
o. Rixubis
p. Voncento
q. Veyvondi
r. Wilate
s. Willfact
t. Alphanate
u. Octanate
v. Optivate
w. Fahndi
x. Haemate

3. In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)

    a. Hemlibra (non-inhibitor patients)
    b. Hemlibra (inhibitor patients)
    c. Advate
    d. Adynovi
    e. Elocta
    f. Esperoct
    g. NovoEight
    h. ReFacto AF
    i. Nuwiq
    j. Idelvion
    k. Refixia
    l. Alprolix
    m. BeneFIX
    n. Replenine
    o. Rixubis
    p. Voncento
    q. Veyvondi
    r. Wilate
    s. Willfact
    t. Alphanate
    u. Octanate
    v. Optivate
    w. Fahndi
    x. Haemate

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 3, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested, the UHB would need to undertake a manual trawl of all of the identified prescriptions and cross reference with the patient's medical record, to identify the information that would fulfil this part of your request, as it is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds for questions 1 and 2 overleaf.

1. The UHB provides, within the table below, the number of Haemophilia A, Haemophilia B and von Willebrand patients that were treated with the listed coagulation factors, during the period 1 July to 30 September 2023.

	Coagulation factor	Number
a.	Hemlibra (non-inhibitor patients)	0
b.	Hemlibra (inhibitor patients)	0
c.	Advate	*
d.	Adynovi	0
e.	Elocta	0
f.	Esperoct	0
g.	NovoEight	0
h.	ReFacto AF	0
i.	Nuwiq	0
j.	Idelvion	0
k.	Refixia	*
l.	Alprolix	0
m.	BeneFIX	0
n.	Replenine	0
o.	Rixubis	0
p.	Voncento	0
q.	Veyvondi	0
r.	Wilate	0
s.	Willfact	0
t.	Alphanate	0
u.	Octanate	0
v.	Optivate	0
w.	Fahndi	0
x.	Haemate	0

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. The UHB provides, within the table below, the volume used, in International Unit (IU), of the listed coagulation factors, during the period 1 July to 30 September 2023.

	Coagulation factor	IU
a.	Hemlibra (non-inhibitor patients)	0
b.	Hemlibra (inhibitor patients)	0
c.	Advate	41,000
d.	Adynovi	0
e.	Elocta	0
f.	Esperoct	0
g.	NovoEight	0
h.	ReFacto AF	0
i.	Nuwiq	0
j.	Idelvion	0
k.	Refixia	40,000
l.	Alprolix	0
m.	BeneFIX	0
n.	Replenine	0
o.	Rixubis	0
p.	Voncento	0
q.	Veyvondi	0
r.	Wilate	0
s.	Willfact	0
t.	Alphanate	0
u.	Octanate	0
v.	Optivate	0
w.	Fahndi	0
x.	Haemate	0